Primary Safety Endpoint: • Incidence of all adverse events by severity, related or unrelated to the study drug. Primary Efficacy Endpoint: • Rate of improvement of COVID-19 status on Day 7 (2 days post last therapy), transitioning from “Severe” to at least “Moderate” or from “Moderate” to “Moderate-Mild” using the 10-point COVID-19 clinical severity ordinal scale

Primary Safety Endpoint: • Incidence of all adverse events by severity, related or unrelated to the study drug. Primary Efficacy Endpoint: • Rate of improvement of COVID-19 status on Day 7 (2 days post last therapy), transitioning from “Severe” to at least “Moderate” or from “Moderate” to “Moderate-Mild” using the 10-point COVID-19 clinical severity ordinal scale